Drugmakers Push Back Against Proposed Exclusion Criteria for Rare Esophageal Disease Trial

Drug Industry Daily
A A
Two drug companies are pushing back against proposed FDA guidance that would require drug sponsors to hold pre-trials to determine whether patients with a nasty form of esophageal swelling could benefit from an alternate therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily